SMN2 and proximal spinal muscular atrophy: Effectiveness of this treatment was tested initially using a mild mouse model of SMA at embryonic, neonatal, and adult stages and it was noted that SMN protein levels were increased resulting in an improvement of the SMA phenotype (Hua et al., 2010).